Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thimerosal, MMR Vaccines Not Associated With Autism, IoM Report Concludes

This article was originally published in The Pink Sheet Daily

Executive Summary

Report updates 2001 reports that were “unclear” about link between thimerosal and neurodevelopment disorders.

You may also be interested in...



Sanofi-Aventis Removes Thimerosal From Adult Tetanus/Diphtheria Vaccine

Decavac will be priced at a 78% premium to the discontinued thimerosal-containing version of the vaccine due to additional manufacturing and packaging costs. The company is working with FDA to reduce or remove thimerosal from all its vaccine products.

Sanofi-Aventis Removes Thimerosal From Adult Tetanus/Diphtheria Vaccine

Decavac will be priced at a 78% premium to the discontinued thimerosal-containing version of the vaccine due to additional manufacturing and packaging costs. The company is working with FDA to reduce or remove thimerosal from all its vaccine products.

Vaccine Safety Body Proposed To Remove FDA "Conflict Of Interest"

A proposal to move post-market vaccine safety surveillance to an independent board will be discussed by the National Vaccine Advisory Committee at its next meeting. FDA and CDC are defending the current system as enabling communication between risk management and risk assessment staff.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel